Project Grant R01HL175515
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$597K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $244,589 award supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). Key objectives include examining the regulation and activation of VPS34 in the pulmonary vasculature of PAH patients, determining the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $587,749 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota. The objective of this 4-year grant, with a performance period from July 1, 2024 to April 30, 2028, is to investigate the role of endoplasmic reticulum-mitochondria contact sites in right ventricular fibrosis. The research aims to establish the molecular mechanisms by which C-Src-dependent...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $522,794 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois to investigate the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The grant aims to elucidate the molecular mechanisms by which HV1 regulates the progression of pulmonary hypertension and explore the potential of HV1 blockers as a treatment approach. The project will utilize transgenic...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $498,000.00 to National Jewish Health in Denver, Colorado to conduct research on the role of RNA editing in pulmonary hypertension. The primary objective is to investigate how the enzyme ADAR1, which regulates RNA editing, controls the survival and immune response of pulmonary artery endothelial cells and impacts the...
The federal Project Grant award K08HL173620, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research grant program (CFDA 93.837), supports research to examine the role of mTOR hyperactivation in pulmonary vascular remodeling and its contribution to the development and progression of pulmonary hypertension (PH). The $164,700 award, with a project period from August 15, 2024 to July 31, 2029, will leverage novel mouse models and primary lung...
This federal Project Grant award, valued at $616,000.00 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The funded project aims to determine whether an increased mitochondrial NADH/NAD+ ratio and activation of the integrated stress...
This federal Project Grant award in the amount of $692,768 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to define endothelial cell dysfunction and anoikis resistance in patients with pulmonary arterial hypertension (PAH). The research aims to leverage a "cell biopsy" method to characterize endothelial cell phenotypes and identify key mediators of anoikis resistance...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 2-year, $131,485 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. to study the role of proline metabolism in pulmonary arterial hypertension (PAH). The research aims to understand how inflammation impairs the regulation of proline in pulmonary artery endothelial cells, potentially leading to increased cell proliferation, collagen synthesis, and vascular remodeling in early-stage...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research focused on understanding the role of the RNA-binding protein ZFP36 in pulmonary arterial hypertension (PAH). The $1,535,625 award, effective July 20, 2024 through May 31, 2028, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how ZFP36 regulates gene expression and impacts...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will fund research to investigate the role of alternative polyadenylation (APA) in right ventricular (RV) fibrosis associated with pulmonary hypertension (PH). The $760,708 award, with a project period from September 25, 2024 to September 24, 2025, will be used by the awardee, The Methodist Hospital Research Institute (HMRI), to:...